Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:eneration of diffuse large B cell lymphomaassociated antigen-specific Va6/Vb13+T cells by TCR gene transfer | Yin et al. Journal of Hematology Oncology 2011 4 2 http content 4 1 2 JOURNAL OF HEMATOLOGY ONCOLOGY RESEARCH Open Access Generation of diffuse large B cell lymphoma-associated antigen-specific Va6 Vp13 T cells by TCR gene transfer 1 1 1 1 2 1 13 Qingsong Yin Xianfeng Zha Lijian Yang Shaohua Chen Yubing Zhou Xiuli Wu Yangqiu Li Abstract Background Our previous study had amplified antigen-specific full-length TCR a and b genes of clonally expanded T cells in the peripheral blood PB of patients with diffuse large B-cell lymphoma DLBCL . The transfer of T cell receptor TCR genes endows T cells with new antigen specificity. Therefore the aim of this study is to generate diffuse large B cell lymphoma DLBCL -specific T cells by T cell receptor TCR gene transfer. Materials and methods Two different eukaryotic expression plasmids harboring TCR Va6 and TCR Vb 13 genes specific for DLBCL-associated antigens were constructed and subsequently transferred into human T cells using Nucleofector technique. The expression of targeted genes in TCR gene-modified cells was detected by real-time PCR and western blot using TCR Vb antibody. The specific cytotoxicity of TCR gene-transferred T cells in vitro was estimated using a lactate dehydrogenase LDH release assay. Results Two different eukaryotic expression plasmids harboring TCR Va6 and TCR Vb 13 genes specific for DLBCL-associated antigens were constructed and subsequently transferred into T cells from healthy donors. Specific anti-DLBCL cytotoxic T lymphocytes CTL could be induced by transduction of specific TCR gene to modify healthy T cells. The transgene cassette of TCR Vb13-IRES-TCR Va6 was superior to the other in the function of TCR-redirected T cells. Conclusions Specific anti-DLBCL cytotoxic T lymphocyte CTL could be inducted by transduction of specific TCR gene to modify healthy T cells. Background In the past two decades fundamental advances in immunology have introduced cellular-based therapies for .
